Latest News Archive

Please select Category, Year, and then Month to display items

The Africa we want

27 June 2023 | Story Valentino Ndaba | Photo Charl Devenish

“The Africa we want can only be achieved by promoting good governance, democracy, respect for human rights, justice and the rule of law, a peaceful and secure Africa with a strong cultural identity, common heritage, values, and ethics,” said Shelton Makore, Senior Law Lecturer in the University of the Free State Department of Mercantile Law.

He further remarked that, “Such an approach will enable Africa to have economic, political, and social development that is people-driven, relying on the potential offered by the people of Africa, especially its women and youth, caring for children, and an Africa that is strong, united, resilient, and an influential global player and partner.”

Makore's statement encapsulated a concise summary of the dialogue he moderated, which took place during Africa Month and was organised by the Faculty of Law. The main purpose of the dialogue was to delve into the African Union's Agenda 2063, titled ‘The Africa we want’, with a specific focus on advancing justice in Africa to achieve sustainable development. The discussions revolved around the idea of fostering a politically united and integrated continent that embraces the principles of Pan-Africanism and the vision of African Renaissance.

Looking back on Africa Month

The Faculty of Law hosted a two-tier Africa Day event on the Bloemfontein Campus on 25 May 2023. It included a round-table dialogue on 'Advancing Justice with a View of the Future: The 2063 Agenda for Sustainable Development' and a cultural exhibition titled: 'Appreciating Knowledge through Culture'.

Prof Danie Brand, Director of the Free State Centre for Human Rights at the UFS, Ntando Sindane, Lecturer in the Department of Private Law, and Dr Isolde de Villiers, Senior Lecturer in the Department of Mercantile Law, were part of the panel of experts who facilitated a discussion that looked through the lens of seven aspirational themes:

A prosperous Africa, based on inclusive growth and sustainable development
An integrated continent, politically united and based on the ideals of Pan-Africanism and the vision of African Renaissance
An Africa of good governance, democracy, respect for human rights, justice, and the rule of law
A peaceful and secure Africa
Africa with a strong cultural identity, common heritage, values, and ethics
An Africa whose development is people-driven, relying on the potential offered by African people, especially its women and youth, and caring for children
An Africa as a strong, united, resilient, and influential global player and partner

Africa’s futureEnvisioning

During the discussion, Prof Brand underscored the importance of fostering cultural diversity as a means to achieve inclusivity and a sustainable future. On the other hand, Sindane highlighted the necessity of engaging in self-reflection and adapting to the challenges posed by neoliberal and neo-colonial economic structures, aiming to address poverty, hunger, and deprivation in Africa. The panellists delved into a comprehensive exploration of the Sustainable Development Goals and their significant role in shaping the desired future for Africa. Dr De Villiers highlighted the impact of spatial injustice on people's lives, emphasising the need for fair and equitable distribution of resources and opportunities within cities and towns.

The dialogue generated valuable insights on repositioning Africa as a beacon of hope, inclusivity, justice, and prosperity, aligning with the UFS Vision 130 strategic plan. Additionally, the exhibition added to the dialogue's impact, featuring impressive displays of cultural attire, food, and artefacts by students representing diverse African countries.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept